COMPARTIVE ANIMAL CORE

比较动物核心的总体目标是支持本计划项目拨款中使用的动物模型的开发和使用。比较动物核心的指导原则是有效规划和利用组织和肿瘤样本，标准化处理和诊断，以及犬自发性肿瘤动物模型的持续发展。该中心由俄勒冈州立大学兽医学院兽医生物科学系负责协调，包括在比较病理学、组织库和临床试验开发和执行方面具有专业知识的个人。Cheryl London博士是董事会认证的兽医学肿瘤学家，在癌症药物开发方面拥有广泛的专业知识，包括验证新靶点，确定适当的小分子靶点抑制，以及在相关犬类癌症中测试这些化合物，目的是提供有助于人类药物开发过程的关键信息。Drs。Krista La Perie和Brad Bolon是共同研究人员，他们是兽医解剖病理学委员会认证的专家，也是比较病理学领域的专家，特别是在癌症小鼠模型和这些模型中新疗法的评估方面。本核心的主要目的是协助研究人员确定小鼠肉瘤模型中与新治疗方法相关的毒性和活性，确定可能在临床环境中取得成功的候选药物/治疗方法，并在患有自发性肉瘤的狗身上评估这些治疗方法，作为未来人类临床试验的前驱。因此，该核心的具体目标是：1)为各种靶向治疗后在疾病小鼠模型中产生的肉瘤提供标准化的组织病理学评估；2)确定与新疗法治疗小鼠相关的不良反应。3)为自发性肉瘤犬提供高质量的正常和肿瘤组织样本；4)评估一种新型STATS抑制剂（LY5）在正常犬和自发性骨肉瘤犬中的不良事件概况和生物活性。

The overall goal ofthe comparative animal core is to support the development and use ofthe animal models employed within this Program Project Grant. The guiding principals for the comparative animal core are efficient planning and utilization of tissue and tumor samples, standardization of processing and diagnoses, and continued development of the canine spontaneous tumor animal model. This Core is housed and coordinated in the Department of Veterinary Biosciences in the College of Veterinary Medicine at OSU and includes individuals with expertise in comparative pathology, tissue banking, and clinical trial development and execution. Dr. Cheryl London, the proposed Core Director, is a Board Certified Veterinary Medical Oncologist with extensive expertise in cancer drug development including validating novel targets, identifying appropriate small molecules for target inhibition, and testing these compounds in relevant canine cancers with the goal of providing critical information that can assist in the human drug development process. Drs. Krista La Perie and Brad Bolon, Co-Investigators, are Board Certified in Veterinary Anatomic Pathology and are experts in the field of comparative pathology, particularly with respect to mouse models of cancer and evaluation of novel therapeutics in these models. The primary objective of this Core is to assist investigators in determining both the toxicities and activity associated with novel therapeutic approaches in mouse models of sarcoma, to identify candidate drugs/treatments that are likely to have success in the clinical setting, and to evaluate these treatments in dogs with spontaneous sarcomas as a prelude to future human clinical trials. As such, the specific aims of this Core are to: 1) Provide a standardized histopathologic evaluation of sarcomas generated in mouse models of disease following treatment with various targeted therapeutics; 2) Identify adverse effects associated with treatment of mice with novel therapeutics. 3) Provide high quality normal and tumor tissue samples from dogs with spontaneous sarcomas; and 4) Assess the adverse event profile and biologic activity of a novel STATS inhibitor (LY5) in normal dogs and dogs with spontaneous osteosarcoma.